USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $3.25 | $2.47 | $2.08 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $264.00M | $153.62M | $101.72M |
Fulgent Genetics's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $1.89 | $1.89 | $1.89 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $14.24 | $14.24 | $14.24 |
| Dec 2022 | 1 | $5.60 | $5.60 | $5.60 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $1.59 | $1.40 | $1.45 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 0 | $12.25 | $12.32 | $12.45 |
| Dec 2022 | 1 / 0 | $3.82 | $3.26 | $3.36 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $171.20M | $171.20M | $171.20M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $948.20M | $948.20M | $948.20M |
| Dec 2022 | 1 | $534.80M | $534.80M | $534.80M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $3.25 | - | - |
| Aug 9, 2021 | Jun 2021 | $2.67 | $2.47 | -7.58% |
| May 6, 2021 | Mar 2021 | $5.70 | $6.52 | 14.39% |
| Mar 4, 2021 | Dec 2020 | $4.05 | $6.20 | 52.96% |
| Nov 9, 2020 | Sep 2020 | $0.55 | $2.08 | 278.18% |
| Aug 4, 2020 | Jun 2020 | $0.01 | $0.17 | 1600.00% |
| May 4, 2020 | Mar 2020 | $0.02 | $-0.03 | -242.86% |
| Mar 10, 2020 | Dec 2019 | $0.02 | $0.04 | 105.13% |
| Nov 4, 2019 | Sep 2019 | $0.03 | $0.14 | 366.67% |
| Aug 5, 2019 | Jun 2019 | $-0.00 | $0.06 | 3100.00% |
| May 7, 2019 | Mar 2019 | $-0.01 | $-0.06 | -361.54% |
| Feb 28, 2019 | Dec 2018 | $-0.02 | $-0.01 | 33.33% |
| Nov 6, 2018 | Sep 2018 | $-0.03 | $-0.03 | -32.00% |
| Aug 6, 2018 | Jun 2018 | $-0.03 | $-0.01 | 66.67% |
| May 7, 2018 | Mar 2018 | $-0.04 | $-0.06 | -71.43% |
| Feb 28, 2018 | Dec 2017 | $-0.02 | $-0.06 | -268.10% |
| Nov 6, 2017 | Sep 2017 | $0.02 | $-0.02 | -183.33% |
| Aug 7, 2017 | Jun 2017 | $0.02 | $0.02 | 25.00% |
| May 8, 2017 | Mar 2017 | $0.06 | $0.03 | -45.45% |
| Feb 27, 2017 | Dec 2016 | $0.07 | $0.06 | -12.79% |
| Nov 3, 2016 | Sep 2016 | $0.09 | $0.11 | 16.40% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 4, 2021 | Dec 2020 | $6.28 | $8.42 | 34.08% |
| Mar 10, 2020 | Dec 2019 | $0.17 | $0.18 | 5.88% |
| Feb 28, 2019 | Dec 2018 | $-0.10 | $-0.11 | - |
| Feb 28, 2018 | Dec 2017 | $0.01 | $-0.03 | - |
| Feb 27, 2017 | Dec 2016 | - | $0.17 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $264.00M | - | - |
| Aug 9, 2021 | Jun 2021 | $153.62M | $153.62M | 1.00% |
| May 6, 2021 | Mar 2021 | $321.51M | $359.43M | 1.12% |
| Mar 4, 2021 | Dec 2020 | $199.44M | $294.98M | 1.48% |
| Nov 9, 2020 | Sep 2020 | $48.46M | $101.72M | 2.10% |
| Aug 4, 2020 | Jun 2020 | $10.02M | $17.27M | 1.72% |
| May 4, 2020 | Mar 2020 | $7.74M | $7.75M | 1.00% |
| Mar 10, 2020 | Dec 2019 | $8.51M | $8.39M | 0.99% |
| Nov 4, 2019 | Sep 2019 | $8.45M | $10.35M | 1.22% |
| Aug 5, 2019 | Jun 2019 | $6.42M | $8.42M | 1.31% |
| May 7, 2019 | Mar 2019 | $5.60M | $5.37M | 0.96% |
| Feb 28, 2019 | Dec 2018 | $5.84M | $5.67M | 0.97% |
| Nov 6, 2018 | Sep 2018 | $5.38M | $5.62M | 1.05% |
| Aug 6, 2018 | Jun 2018 | $4.93M | $5.40M | 1.10% |
| May 7, 2018 | Mar 2018 | $5.12M | $4.65M | 0.91% |
| Feb 28, 2018 | Dec 2017 | $5.12M | $4.28M | 0.84% |
| Nov 6, 2017 | Sep 2017 | $5.61M | $4.50M | 0.80% |
| Aug 7, 2017 | Jun 2017 | $4.81M | $4.64M | 0.96% |
| May 8, 2017 | Mar 2017 | - | $5.31M | - |
| Feb 27, 2017 | Dec 2016 | - | $5.85M | - |
| Nov 3, 2016 | Sep 2016 | - | $5.01M | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 4, 2021 | Dec 2020 | $326.20M | $421.71M | 29.28% |
| Mar 10, 2020 | Dec 2019 | $32.67M | $32.53M | -0.43% |
| Feb 28, 2019 | Dec 2018 | $21.52M | $21.35M | -0.79% |
| Feb 28, 2018 | Dec 2017 | $19.58M | $18.73M | -4.34% |
| Feb 27, 2017 | Dec 2016 | - | $18.28M | - |
FLGT's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 1 analysts, the average EPS estimation for Fulgent Genetics's next quarterly earnings is $3.25, with a low EPS estimation of $3.25, and a high estimation of $3.25.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $1.29, the last 2 month trend is $1.61, and the 3 month trend is $1.72.
Based on 3 analysts, the average revenue estimation is $264.00M, with a low revenue estimation of $264.00M, and a high estimation of $264.00M.
Fulgent Genetics's previous earnings date was Aug 9, 2021 for its fiscal quarter ended Jun 30, 2021.
FLGT's earnings per share (EPS) was $2.47, missing the consensus analysts forecast of $2.67 by -7.58%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by -62.15%, and higher than the same period a year before (Jun 2020) by 1351.59%.
Revenues were $153.62M, better than the forecast of $153.62M by 0.00%, down by -57.26% from the previous quarter , and up by 789.75% from the same period last year.
The company reported a net income of $79.81M, -60.23% lower than the previous quarter, and higher by 2303.25% than the same period a year before.
Free cash flow for the quarter was $73.18M , compared to $221.69M last quarter and $-4.82M a year before.
FLGT ended the quarter with $21.98M in total debt, an increase of 46.05% compared to the previous quarter, and an increase of 667.35% compared to the same quarter a year before.
Fulgent Genetics's previous annual earnings date was Mar 4, 2021 for its fiscal year ended Dec 31, 2020.
FLGT's earnings per share (EPS) was $8.42, beating the consensus analysts forecast of $6.28 by 34.08% , and higher than the previous year's EPS (Dec 2019) by 4577.78%.
Revenues were $421.71M, better than the forecast of $326.20M by 29.28%, and up by 1196.46% from previous year's revenue.
The company reported a net income of $214.31M.
Fulgent Genetics reported a free cash flow of $104.12M for its fiscal year, compared to $4.20M a year ago.
The company ended the fiscal year with $15.85M in total debt, an increase of 492.45% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
